Omya announced that results of a recent in vitro study that compared the bioavailability of its newly developed source of calcium, Omyaforte 100, with other frequently used calcium salts.
Photo © iStockphoto.com/nicolas_
Omya (Oftringen, Switzerland) announced that results of a recent in vitro study that compared the bioavailability of its newly developed source of calcium, Omyaforte 100, with other frequently used calcium salts, namely calcium citrate tetrahydrate, tri-calcium phosphate, and calcium carbonate. According to the study, Omyaforte exhibited a higher percentage of elemental calcium and excellent bioavailability compared to the other calcium sources.
The ingredient is a modified calcium carbonate with hydroxyapatite. According to the researchers, the ingredient’s performance can be attributed to the amorphous structure of the hydroxyapatite, which when combined with calcium carbonate creates greater porosity, lower agglomerates, and particle size to improve the solubility of calcium.
Because of its innovative composition and structure, says Omya, Omyaforte 100 is well-suited to applications with a high content of bioavailable calcium such as bone health mixtures, rehydration solutions and other powdered supplements. It can also be combined with a broad range of other bone health ingredients such as vitamin D and biopeptides. Therefore, the new mineral solution is ideal for athletes and “healthy agers” alike, as well as those who are avoiding dairy in their diet.
Reference
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.